Millendo Therapeutics, Inc.
MLND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $570 | $3,871 | $7,627 | $15,629 |
| G&A Expenses | $3,027 | $4,095 | $3,309 | $446 |
| SG&A Expenses | $3,027 | $4,095 | $3,309 | $446 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,597 | $7,966 | $10,936 | $16,075 |
| Operating Income | -$3,597 | -$7,966 | -$10,936 | $25,951 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $86 | $96 | $76 | -$41,675 |
| Pre-Tax Income | -$3,511 | -$7,870 | -$10,860 | -$15,724 |
| Tax Expense | $0 | $0 | $0 | -$108 |
| Net Income | -$3,511 | -$7,870 | -$10,860 | -$15,724 |
| % Margin | – | – | – | – |
| EPS | -0.79 | -2.07 | -3.16 | 19.11 |
| % Growth | 61.8% | 34.5% | -116.5% | – |
| EPS Diluted | -0.79 | -2.07 | -3.16 | 19.11 |
| Weighted Avg Shares Out | 4,440 | 3,803 | 3,438 | 27,902 |
| Weighted Avg Shares Out Dil | 4,440 | 3,803 | 3,438 | 27,902 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $86 | $46 | $161 | $1,592 |
| Depreciation & Amortization | $66 | $0 | $0 | -$630 |
| EBITDA | -$3,359 | -$7,966 | -$10,936 | -$18,054 |
| % Margin | – | – | – | – |